Fundraising FoxVenture-Backed Startups
142,610 companies with verified investor relationships.
A commercial real estate building located in Manhattan's Ladies' Mile district, presented as a leasing property with retail and building specifications available. The site markets the property, which is managed or owned by RXR.
1 investor
0 investors
0 investors
0 investors
0 investors
0 investors
Agriculture technology company; sold to Monsanto.
1 investor
640 Oxford is an early-stage venture capital firm investing in areas such as smart factory technology and automation, logistics for the movement of goods, predictive maintenance and autonomous systems, and workforce productivity tools. It positions itself as a hands-on partner to founders at the earliest stages, with a presence spanning Silicon Valley and the Midwest.
1 investor
0 investors
0 investors
0 investors
0 investors
64x provides a platform and product suite for manufacturing advanced therapeutics, including gene therapies, cell therapies, and biologics. The company uses massively parallelized screening and computational insights to engineer high-yield cell lines and production technologies that accelerate the manufacturing of next-generation medicines.
2 investors
64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.
6 investors
0 investors
0 investors
0 investors
0 investors
65LAB accelerates drug discovery and therapeutic company formation by connecting academic research institutions, life science investors, and Evotec to develop novel medicines into commercial entities. The organization identifies promising therapeutic projects, provides funding up to USD 1.5 million, and mentoring to achieve preclinical proof-of-concept before potential spinout.
1 investor
0 investors
脑动极光 (66nao) develops medical-grade digital therapeutics that combine brain science with AI to assess and treat cognitive impairment caused by vascular disease, neurodegenerative disease, psychiatric disorders, and childhood developmental deficits. It operates in China's cognitive disorder digital therapeutics market and states its core product was the first regulator-approved cognitive disorder digital therapeutic in China.
1 investor
0 investors
0 investors
0 investors